Loading...

SLNO SOLENO THERAPEUTICS INC Capital Structure Changes 8-K Filing

SLN

SLN

SOLENO THERAPEUTICS INC

(SLNO)

2024 8-K

Show Summary

Show Summary

Financial Statements

Accountant Change

Financial Results

Executive Compensation

FDA Review Extension

Financial Results

Financial Results Announcement

Sale Agreement with Jefferi...

Stock Grants to Employees

Lease Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Public Offering of Common S...

FDA Breakthrough Therapy De...

Amendment to Inducement Equ...

Compensation Increase

Public Offering and Private...

Termination of Sales Agreement

Regulation FD Disclosure

Appointment of Director

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results and Equit...

Completion of Enrollment in...

Financial Results Announcement

Amendment to Inducement Plan

Compensation Increases for ...

External Links:

Soleno Therapeutics entered into a loan agreement for up to $200 million, initially drawing $50 million, to support the development of DCCR for Prader-Willi syndrome, with loans maturing in 2029 and interest rates between 7.50% and 12.62%.

AI Assistant

SOLENO THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.